John T. Treace Sells $50.7K of Treace Medical Concepts Inc (TMCI) — SEC Form 4, Mar 10, 2023

Open-Market Net Sale · SEC Form 4
−$50,651

Equity position changed by +0.7%

Reporting Owner
John T. Treace
Officer 10% Owner
TXN 2023-03-10 · FILED 2023-03-10
Equity Position 10.9M sh 10,865,584 → 10,945,984
Equity Change +0.7% shares held after vs before
Filing Lag 0 business days within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership

Treace Medical Concepts Inc

TMCI CIK 0001630627
All Treace Medical Concepts Inc insider activity
Filing Date
2023-03-10
Report Date
2023-03-09
Accession No.
0001209191-23-018046
Accepted At
2023-03-11 02:00 UTC
Reporting Owner
Name Relationship
John T. Treace CIK 0001856380
Director Officer 10% Owner
John T. Treace at Treace Medical Concepts Inc Full insider history
Bought (12 mo) $1,351,631
Sold (12 mo) —
More from this insider at Treace Medical Concepts Inc
2026-08-24 Buy +$246,654 View
2026-06-11 Buy +$210,968 View
2026-06-01 Buy +$177,915 View
2026-05-28 Buy +$340,589 View
2026-05-14 Buy +$375,505 View
All filings by this insider at Treace Medical Concepts Inc
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Common StockF1F2 2023-03-09 S - Sale 2,075 D $24.41 -$50,651 5,539,380 Direct
Common StockF3F4 2023-03-10 A - Award/Grant 82,475 A $0.00 — 5,621,855 Direct
Derivative Securities Transactions
Title Strike Date Type Shares Price Expiration Underlying Ownership
Stock Option (Right to Buy)F7 $24.07 2023-03-10 A - Award/Grant 186,900 A $0.00 2033-03-10 186,900 Stock Option (Right to Buy) Direct
Non-Derivative Holdings
Title Shares Held Ownership
Common StockF5 1,605,000 Indirect
Common StockF5 1,471,250 Indirect
Common StockF6 1,839,063 Indirect
Common StockF6 408,816 Indirect
Footnotes (7)
F1
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Show more
F2
Includes 25,406 restricted stock units. Show more
F3
Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 10, 2024 with the last installment on March 10, 2027; subject to Reporting Person's providing continued service to Issuer through each vesting date. Show more
F4
Includes 107,881 RSUs. Show more
F5
The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. Show more
F6
The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as Trustee or Co-Trustee. Show more
F7
The stock option will vest in equal annual installments over 4 years, commencing on March 10, 2024 with the last installment on March 10, 2027; subject to Reporting Person's providing continued service to Issuer through each vesting date. Show more

Related filings at Treace Medical Concepts Inc

Institutional Holders
13F holders · Jun 30, 2026 115 institutional managers reporting a position
Largest by reported value
  1. Armistice Capital, Llc $25.3M
  2. Bank Of America Corporation $13.2M
  3. Gagnon Securities Llc $12.1M
5%+ Holders · 13D/G 4 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Treace Medical Concepts Inc
All Treace Medical Concepts Inc insider activity
GET /v1/forms/4/0001209191-23-018046 API docs
View Original SEC Filing